TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES

Courtesy of SBHCI.

This new device has, on one hand, an abluminal sirolimus coating, and on the other hand, a luminal CD34 antibody coating for EPC capturing, to potentially accelerate post-PCI reendothelization.

Between 2014 and 2016, the study included 1496 patients undergoing acute coronary syndrome (ACS), receiving the new COMBO stent. These patients were randomized to 3 and 12 months of dual APT. Primary end point was a composite of death, infarction, stent thrombosis, stroke, revascularization and bleeding at 12 months.

Read also: “TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device”.

There were no differences in events between months 3 and 12 of DAPT (8.2% vs 8.4%, for non-inferiority < 0.001). There were no differences in major bleeding (2.5% vs 3%), death (1.9% vs 0.8%) or definite/probable thrombosis (1.2% vs 0.4%). However, the study did not have enough statistical power to assess these events separately.

Conclusion

The REDUCE study showed that 3 months DAPT are non-inferior to 12 months DAPT in ACS patients treated with the COMBO stent.

Courtesy of SBHCI.

Original title: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS.

Presenter: Harry Suryapranata.

REDUCE

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.